Replimune has commercially launched TUDRIQEV, a novel oncolytic immunotherapy for advanced melanoma, in the U.S., with over 15 institutions prescribing it since early October. The treatment is used in combination with nivolumab for patients progressing after PD-1 therapy and is supported by broad label and payer coverage. The company reported a net loss of $57.1 million for Q2 2027 but holds $307.8 million in cash, supporting operations for over a year. Ongoing Phase 3 and Phase 2/3 trials aim to confirm clinical benefits and expand indications.
Replimune's recent financial results come as 42 of 150 priced Health-sector US stocks tradable on Pluang rose while 94 fell. For readers following health stocks, here is Pluang's market snapshot as of Oct 28, 2026 17:41 WIB: TWST (Twist Bioscience Corp) rose 1.97% to USD 163.00 with 100% buy orders and a typical hold time of 27 days; MRNA (Moderna, Inc.) fell 1.87% to USD 204.09 with 80% sell orders and a typical hold time of 58 days; IMVT (Immunovant Inc. Common Stock) rose 1.80% to USD 29.40 with a typical hold time of 19 days.
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
The Legacy Lab by Team One released its 2026 Legacy Makers 100 list, identifying brands consumers trust to have their best interests at heart and remain relevant long-term. St. Jude Children's Research Hospital topped the list for the second year. Th...
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Grabar Law Office is investigating claims against officers and directors of Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company for alleged breaches of fiduciary duties. The investigations focus on misleading statements and...
